Extension Study for Study ALT-103-201: One-year Follow-up for the 1×10(11th) vp NasoVAX Group
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Influenza virus vaccine (NasoVAX) (Primary)
- Indications Influenza A virus infections
- Focus Pharmacodynamics
- Sponsors Altimmune
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 16 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 21 Jan 2019.
- 29 Nov 2018 Status changed from planning to not yet recruiting.